Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VX-103 H1 Influenza Vaccine Patch in Healthy Adults
NCT06125717Phase 1Completed
- Sponsor
- Vaxess Technologies
- Start
- Jul 2022
- Primary completion
- Mar 2023
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of VX-103 in influenza (3 arms), sponsored by Vaxess Technologies. Primary endpoint: Safety, Reactogenicity, and Tolerability at 180 days. Started Jul 2022; status: completed.
02
Drugs
VX-103
03
Conditions
influenza
Beyond the preview
Go deeper on NCT06125717.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06125717.